JP2012516358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012516358A5 JP2012516358A5 JP2011548359A JP2011548359A JP2012516358A5 JP 2012516358 A5 JP2012516358 A5 JP 2012516358A5 JP 2011548359 A JP2011548359 A JP 2011548359A JP 2011548359 A JP2011548359 A JP 2011548359A JP 2012516358 A5 JP2012516358 A5 JP 2012516358A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition according
- cancer
- anticancer composition
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 45
- 230000001093 anti-cancer Effects 0.000 claims 38
- 239000003112 inhibitor Substances 0.000 claims 26
- 230000001413 cellular effect Effects 0.000 claims 17
- 239000006177 biological buffer Substances 0.000 claims 11
- 150000001720 carbohydrates Chemical class 0.000 claims 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 4
- 229910052783 alkali metal Inorganic materials 0.000 claims 4
- 150000001340 alkali metals Chemical class 0.000 claims 4
- 239000007979 citrate buffer Substances 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000000600 sorbitol Substances 0.000 claims 4
- 235000010356 sorbitol Nutrition 0.000 claims 4
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 3
- 239000008351 acetate buffer Substances 0.000 claims 3
- 150000004703 alkoxides Chemical group 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 239000006227 byproduct Substances 0.000 claims 3
- 150000007942 carboxylates Chemical group 0.000 claims 3
- 230000034659 glycolysis Effects 0.000 claims 3
- 150000004820 halides Chemical group 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 3
- 229960000367 inositol Drugs 0.000 claims 3
- 239000008363 phosphate buffer Substances 0.000 claims 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 3
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 2
- -1 C6-C12 aryl group Chemical group 0.000 claims 2
- 102000051325 Glucagon Human genes 0.000 claims 2
- 108060003199 Glucagon Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 2
- 229960004666 glucagon Drugs 0.000 claims 2
- 230000007062 hydrolysis Effects 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 150000002972 pentoses Chemical class 0.000 claims 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 claims 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 claims 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 claims 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 claims 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-M 2-iodoacetate Chemical compound [O-]C(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-M 0.000 claims 1
- UKORLVILOUWVTJ-UHFFFAOYSA-N 3-bromo-2-hydroxypropanoic acid Chemical compound BrCC(O)C(O)=O UKORLVILOUWVTJ-UHFFFAOYSA-N 0.000 claims 1
- RCWFNCXDFSOVLG-UHFFFAOYSA-N 3-chloro-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CCl RCWFNCXDFSOVLG-UHFFFAOYSA-N 0.000 claims 1
- OSLCJYYQMKPZHU-UHFFFAOYSA-N 3-chlorolactic acid Chemical compound ClCC(O)C(O)=O OSLCJYYQMKPZHU-UHFFFAOYSA-N 0.000 claims 1
- CXABZTLXNODUTD-UHFFFAOYSA-M 3-fluoropyruvate Chemical compound [O-]C(=O)C(=O)CF CXABZTLXNODUTD-UHFFFAOYSA-M 0.000 claims 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical group F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- QEWYKACRFQMRMB-UHFFFAOYSA-M fluoroacetate Chemical compound [O-]C(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-M 0.000 claims 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims 1
- 230000002414 glycolytic effect Effects 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229930191479 oligomycin Natural products 0.000 claims 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14838509P | 2009-01-29 | 2009-01-29 | |
| US61/148,385 | 2009-01-29 | ||
| PCT/US2010/022664 WO2010088564A2 (en) | 2009-01-29 | 2010-01-29 | Compositions and methods for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117604A Division JP2015180680A (ja) | 2009-01-29 | 2015-06-10 | 癌治療用組成物及び癌治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012516358A JP2012516358A (ja) | 2012-07-19 |
| JP2012516358A5 true JP2012516358A5 (OSRAM) | 2013-03-14 |
| JP6068803B2 JP6068803B2 (ja) | 2017-01-25 |
Family
ID=42396378
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548359A Active JP6068803B2 (ja) | 2009-01-29 | 2010-01-29 | 癌治療用組成物及び癌治療方法 |
| JP2015117604A Pending JP2015180680A (ja) | 2009-01-29 | 2015-06-10 | 癌治療用組成物及び癌治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117604A Pending JP2015180680A (ja) | 2009-01-29 | 2015-06-10 | 癌治療用組成物及び癌治療方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8022042B2 (OSRAM) |
| EP (1) | EP2391363B1 (OSRAM) |
| JP (2) | JP6068803B2 (OSRAM) |
| KR (1) | KR20110110355A (OSRAM) |
| CN (1) | CN102387801A (OSRAM) |
| AU (1) | AU2010208062B2 (OSRAM) |
| CA (2) | CA2750944C (OSRAM) |
| DK (1) | DK2391363T3 (OSRAM) |
| ES (1) | ES2607211T3 (OSRAM) |
| HR (1) | HRP20161686T1 (OSRAM) |
| HU (1) | HUE032389T2 (OSRAM) |
| IL (1) | IL214349A (OSRAM) |
| NZ (1) | NZ594434A (OSRAM) |
| PL (1) | PL2391363T3 (OSRAM) |
| PT (1) | PT2391363T (OSRAM) |
| SI (1) | SI2391363T1 (OSRAM) |
| WO (1) | WO2010088564A2 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324175B2 (en) * | 2006-02-16 | 2012-12-04 | Young Hee Ko | Compositions and methods for the treatment of cancer |
| EP3284494A1 (en) | 2009-07-30 | 2018-02-21 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| CN103610671A (zh) * | 2013-12-10 | 2014-03-05 | 江苏长泰药业有限公司 | 丙酮酸药物组成及其在制备治疗肺癌药物中的用途 |
| EP3293167A1 (en) | 2016-09-09 | 2018-03-14 | Université Catholique De Louvain | [18f]-labelled lactate derivative as pet radiotracer |
| US10245235B2 (en) | 2016-12-16 | 2019-04-02 | The Charlotte-Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| US10434113B2 (en) | 2016-12-16 | 2019-10-08 | The Charlotte Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| MX2022000938A (es) * | 2017-03-15 | 2022-12-14 | Lunella Biotech Inc | Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas. |
| US20250248956A1 (en) * | 2022-04-06 | 2025-08-07 | Young Hee Ko | Liquid-dispersible halopyruvate formulations and associated methods |
| CN116375769B (zh) * | 2023-03-10 | 2024-12-03 | 云南贵金属实验室有限公司 | 一种双靶点Pt(Ⅳ)抗癌前药及其制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3360633D1 (en) | 1982-02-12 | 1985-10-03 | Unitika Ltd | Anti-cancer device |
| US5800820A (en) | 1989-01-10 | 1998-09-01 | Repligen Corporation | Methods and compositions for treatment of angiogenic diseases |
| US5759837A (en) | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
| US5284786A (en) * | 1992-08-14 | 1994-02-08 | National Semiconductor Corporation | Method of making a split floating gate EEPROM cell |
| US5854067A (en) | 1996-01-19 | 1998-12-29 | Board Of Regents, The University Of Texas System | Hexokinase inhibitors |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| US6284786B1 (en) | 1999-02-16 | 2001-09-04 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Treatment of cancer using lipoic acid in combination with ascorbic acid |
| US20020006915A1 (en) | 2000-02-15 | 2002-01-17 | Mack Strong Vivian E. | Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation |
| US6448030B1 (en) | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| AU2001245766A1 (en) | 2000-03-14 | 2001-09-24 | The Johns Hopkins University School Of Medicine | Arrest of proliferation of highly glycolytic tumors |
| US6670330B1 (en) * | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
| AU2002233916A1 (en) | 2000-08-03 | 2002-04-29 | Albert Einstein College Of Medicine | Isocitrate lyase enzyme from mycobacterium tuberculosis and inhibitory agents to combat persistent infection |
| US7381713B2 (en) | 2000-12-04 | 2008-06-03 | Sioan-Kettering Institute For Cancer Research | Treatment of cancer by reduction of intracellular energy and pyrimidines |
| US7547673B2 (en) * | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
| EP1526865A4 (en) | 2002-08-05 | 2009-09-02 | Mirus Bio Corp | COMPOUNDS FOR TARGETING HEPATIC CELLS |
| US20040126789A1 (en) | 2002-09-05 | 2004-07-01 | Invitrogen Corporation | Compositions and methods for synthesizing nucleic acids |
| US20040229826A1 (en) * | 2002-12-12 | 2004-11-18 | Larry Norton | Dose-dense & sequential adjuvant cancer chemotherapy |
| AU2004204778B2 (en) * | 2003-01-10 | 2008-05-22 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| AU2004206870A1 (en) | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Treatment of benign prostatic hyperplasia using energolytic agents |
| US20060172953A1 (en) * | 2003-01-17 | 2006-08-03 | Threshold Pharmaceuticals Inc. | Treatment of benign prostatic hyperplasia using energolytic agents |
| CA2575367A1 (en) * | 2004-07-28 | 2006-02-23 | Board Of Regents, The University Of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| JP2008540566A (ja) * | 2005-05-12 | 2008-11-20 | スレッシュオールド ファーマシューティカルズ， インコーポレイテッド | ２−デオキシグルコースを用いたがんの処置 |
| US7754693B2 (en) * | 2006-02-16 | 2010-07-13 | Young Hee Ko | Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
| WO2008076964A1 (en) * | 2006-12-18 | 2008-06-26 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production |
-
2010
- 2010-01-29 WO PCT/US2010/022664 patent/WO2010088564A2/en not_active Ceased
- 2010-01-29 KR KR1020117019808A patent/KR20110110355A/ko not_active Ceased
- 2010-01-29 CA CA2750944A patent/CA2750944C/en active Active
- 2010-01-29 CN CN2010800121947A patent/CN102387801A/zh active Pending
- 2010-01-29 US US12/697,169 patent/US8022042B2/en active Active
- 2010-01-29 SI SI201031357A patent/SI2391363T1/sl unknown
- 2010-01-29 HU HUE10736502A patent/HUE032389T2/en unknown
- 2010-01-29 PL PL10736502T patent/PL2391363T3/pl unknown
- 2010-01-29 DK DK10736502.5T patent/DK2391363T3/en active
- 2010-01-29 JP JP2011548359A patent/JP6068803B2/ja active Active
- 2010-01-29 CA CA3024263A patent/CA3024263A1/en not_active Abandoned
- 2010-01-29 AU AU2010208062A patent/AU2010208062B2/en active Active
- 2010-01-29 EP EP10736502.5A patent/EP2391363B1/en active Active
- 2010-01-29 ES ES10736502.5T patent/ES2607211T3/es active Active
- 2010-01-29 HR HRP20161686TT patent/HRP20161686T1/hr unknown
- 2010-01-29 NZ NZ594434A patent/NZ594434A/en not_active Application Discontinuation
- 2010-01-29 PT PT107365025T patent/PT2391363T/pt unknown
-
2011
- 2011-07-28 IL IL214349A patent/IL214349A/en active IP Right Grant
-
2015
- 2015-06-10 JP JP2015117604A patent/JP2015180680A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012516358A5 (OSRAM) | ||
| HRP20161686T1 (hr) | Pripravci i postupci za liječenje raka | |
| RU2013138672A (ru) | Способ, композиция и набор для чистки кишечника | |
| US9370535B2 (en) | Method for treatment of advanced solid tumors | |
| JP2013500986A5 (OSRAM) | ||
| JP2011051993A5 (OSRAM) | ||
| OA12739A (en) | Platinum derivative pharmaceutical formulations. | |
| JP2020183416A (ja) | 疾患の治療方法 | |
| CN105452258B (zh) | 使用双核金(i)化合物用于癌症治疗的方法 | |
| RU2013113965A (ru) | Применение стеарата магния в составах сухого порошка для ингаляции | |
| RU2014112108A (ru) | Составы с производными децитабина | |
| RU2004132856A (ru) | Фармацевтический препарат с модифицированным высвобождением | |
| JP2017502984A5 (OSRAM) | ||
| JP2016527202A5 (OSRAM) | ||
| TWI500421B (zh) | Pharmaceutical composition | |
| US20100311698A1 (en) | Aqueous based pharmaceutical formulations of water-soluable prodrugs of propofol | |
| JP2013504590A5 (OSRAM) | ||
| JP2015534985A5 (OSRAM) | ||
| JP2014530200A5 (OSRAM) | ||
| ES2432222B1 (es) | Composición farmacéutica inyectable de dexketoprofeno y tramadol | |
| ES3024364T3 (en) | Method for preventing precipitation of injectable solution containing p-boronophenylalanine | |
| JP2015518000A5 (OSRAM) | ||
| WO2021049520A1 (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤 | |
| JP2009504604A5 (OSRAM) | ||
| RU2016115376A (ru) | Фармацевтические композиции, содержащие антибактериальные агенты |